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ABSTRACT Antibodies have been used in a diagnostic capacity for many diseases and for identifying serotypes within single spe-
cies of pathogens, notably between the multiple capsular polysaccharide serotypes of Streptococcus pneumoniae. For many years,
thefunctionsofantibodiesininfectionwerethoughttobelimitedtotheopsonizationofmicroorganismsfollowedbyphagocy-
tosisandtotheﬁxingofcomplement.Thethoughtthatantibodiescouldhaveotherfunctionshasemergedonlyrecently.The
studybyYanoandcoworkersfromthelaboratoryofLiise-annePirofskipublishedin mBio[M.Yano,S.Gohil,J.R.Coleman,
C.Manix,andL.-A.Pirofski,mBio2(5):e00176-11,2011]identiﬁesonemechanismwherebynonopsonicantibodiesenhancethe
transformation competence of two S. pneumoniae serotypes, which leads to an increase in genetic exchange and bacterial vari-
abilitywitharesultingpopulationreductionthroughfratricide.Thesenewandrevealingantibodyfunctionswilladdanother
chaptertotheburgeoningstoryofthediversityandversatilityoftheimmuneresponsetobacteria.
S
ince antibodies were ﬁrst described late in the 19th century,
antibodieshavebecomethesinglemosthighlyrecognizedme-
diators of immunity. During the past century, the general public
has also become familiar with the practice of passive immuniza-
tionforthetreatmentofavarietyofinfectionsthatincludetetanus
and rabies. The downside of antibody therapy, a form of hyper-
sensitivity known as serum sickness that develops after exposure
to heterologous immunoglobulins (i.e., from other species), is
also well-known.
Antibodies have been used in a diagnostic capacity for many
diseases and for identifying serotypes within single species of
pathogens (including distinguishing between the multiple capsu-
lar polysaccharide serotypes of Streptococcus pneumoniae), a job
which they still discharge remarkably well. For many years, the
functions of antibodies in infection were thought to be limited to
opsonization of microorganisms followed by Fc receptor-
mediated phagocytosis and to the ﬁxing of complement. The
thought that antibodies could have other functions has only re-
cently emerged.
Today, it is rare to ﬁnd an issue of a medical journal that does
not include a report that uses chimeric monoclonal antibodies as
therapy for any one of a broad spectrum of diseases (1). Conse-
quently, therapeutic monoclonal antibodies are undergoing an
unprecedented and fast expansion in the drug market. This anti-
body “renaissance” is due to the extraordinary success of molec-
ular biology that permitted (i) the grafting of the Fab fragments
fromanimalsourcesontotheFc-bearingdomainsofclass-speciﬁc
humanimmunoglobulins,and(ii)thecreationoftransgenicmice
that can produce human immunoglobulins for the creation of
hybridomas to many diverse immunogens (2).
Other approaches using antibodies have been tested with var-
ious degrees of success and hold much hope of further develop-
ment for speciﬁc infectious and noninfectious diseases. Antibod-
ies have been linked to drugs and radioisotopes to target speciﬁc
organisms and cells without having the effects of broad toxicity.
Thespeciﬁcityoftheantibodycombinedwiththetargetedtoxicity
of a drug or isotope clearly limits undesirable side effects to non-
target tissues. This concept of the “magic bullet” is not new, but it
has received a new jump start with increasing knowledge of the
production and properties of antibodies. In addition, it is now
possible to create single-chain fragments of variable regions
(scFV) and single domains or nanoantibodies that retain thera-
peutic activity and other desirable properties such as speciﬁcity.
The innovative technologies that are applied to monoclonal anti-
body therapy are now indispensable for treatment of diseases that
had no known cure and for improved modalities against certain
types of infection where rapid intervention is required.
Not unexpectedly, in the last few years, new mechanisms of
action for antibodies have been discovered. The versatile collec-
tion of antibody functions that clear microorganisms includes
new ﬁndings such as complement independent-bacteriolytic im-
munoglobulins, which kill several species of Borrelia (3, 4), and
directantimicrobialeffectsongeneexpressioninfungi(5),among
others.
As mentioned above, antibodies are used to identify the sero-
types of S. pneumoniae that are critical for the formulation of the
current pneumococcal vaccines. The most effective type of host
response to S. pneumoniae is centered on antibody binding to the
pneumococcal capsular polysaccharide followed by Fc receptor-
mediated phagocytosis. Moreover, this traditional mechanism of
opsonization-phagocytosis is also thought to be essential for the
response to active immunization with both the 7- and 23-valent
pneumococcal capsular polysaccharide vaccines (6).
Incontrasttothetraditionalunderstandingthatopsonization-
phagocytosis is necessary for pneumococcal clearance, we now
know that there are a number of nonopsonic antibodies to the
capsular polysaccharides that have the capacity to protect both
experimentally and clinically. A number of these nonopsonic an-
tibodies have been identiﬁed and are both polyclonal and mono-
clonal,canbederivedfromhumansandmice,andprotectagainst
pneumonia and sepsis in experimental models.
So, how do these nonopsonic antibodies work? The study by
Yano and coworkers in the laboratory of Liise-anne Pirofski pub-
lished in mBio (7) identiﬁes one mechanism that was heretofore
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mation competence of two S. pneumoniae serotypes, which leads
to an overall increase in genetic exchange and bacterial variability
and sharply lowers the number of organisms. While the bacteri-
cidal end result has obvious therapeutic relevance, the road taken
toelucidatethismechanismisalsoofmuchbiologicalinterestand
onethatcrisscrossesmicrobiologyandimmunologyatmanypoints.
A protective nonopsonic monoclonal antibody (1E2, 1gG1k
speciﬁc for S. pneumoniae serotype 3) induced a higher transfor-
mation frequency in the appropriate strains when added to
competence-stimulating peptide (CSP) than CSP alone or the
otheropsonicsubclass-matchedmonoclonalantibodiesthatwere
used as controls. Moreover, a human monoclonal nonopsonic
IgM had the same effect as 1E2, indicating that this mechanism is
not speciﬁc to the immunoglobulin class. Similar effects obtained
with antibodies to S. pneumoniae serotype 8 also showed that the
induction of transformation efﬁciency could be obtained with
more than one pathogenic strain of pneumococcus and with an-
tibodies derived from both human and mouse hybridomas. Ag-
glutination of the pneumococcus appeared to be a factor in the
induction of higher transformation frequency. Interestingly, ag-
glutination, at least in S. pneumoniae, appears to be a necessary
precondition for achieving the competent phenotype.
Competence-stimulating peptides (CSP) are pheromones se-
creted by S. pneumoniae for interbacterial communication through
theactivationoftheCompathwaythatregulatesgenetictransforma-
tionandthereforeinduces“competence”inthesebacteria,thephys-
iological state that allows incorporation of exogenous DNA. In gen-
eral, CSP released into the medium activates a two-component
system(ComDE)thatresultsintheexpressionofcomX,leadingtothe
upregulation of genes associated with competence (8).
Along these lines, the 1E2 monoclonal antibody induced late
competence and altered gene expression. Incubation of CSP and
antibody with the appropriate speciﬁc type 3 pneumococcus re-
sulted in an induction of comX expression after 8 minutes of in-
cubation, representing a new second wave of expression that fol-
lowed the peak expression induced by CSP alone after 2 min. The
entire process of competence development in S. pneumoniae oc-
curs rapidly, within 15 minutes, a period of time that can easily
encompassthe2-and8-minobservationofupregulationofcomX
in organisms exposed to CSP and the nonopsonic antibody in the
Yanoetal.study(7).Likewise,thecom-inducedregulonhasgenes
that function at different times (9), and these genes are also in-
duced by exposure to the nonopsonic antibodies.
Yano et al. (7) also reveal some interesting ﬁndings regarding
the competent state of S. pneumoniae and the production of lytic
factorsthatarecapableofeliminatingthecellsthatdonotbecome
competent following exposure to CSP (7). Eliminating noncom-
petent cells supports the idea that permissiveness to accept exog-
enous DNA is the preferred condition following an episode of
stress. This killing phenomenon was characterized as “fratricide”
(10) and results in the release of DNA and a number of virulence
factors.YanoandcolleaguesshowthatinductionofcomXexpres-
sion by exposure of S. pneumoniae to CSP and nonopsonic anti-
bodies was followed by marked upregulation in the expression of
genes associated with fratricide (7). The 1E2 antibody alone in-
creased expression of blp bacteriocin genes, irrespective of CSP.
These genes are expressed in stationary cultures and in fratricide
of noncompetent cells. It could be argued that enhancing fratri-
cide,particularlyifdirectedtocellsthatcannotacceptnewgenetic
information, may also work in favor of preserving the competent
cells by the acquisition of resistance factors to the effects of the non-
opsonicantibodies.Likewise,1E2increasedby2-foldthemortalityof
pneumococcusoverandabovethemortalityachievedbyCSPalone.
If conditions are such that the majority of cells in an S. pneu-
moniae culture can accept DNA more readily than before, those
cellscouldwellacquirenewresistancefactors.Inthisscenario,the
randomacquisitionofnewgenescouldresultintheexpressionof
new antigens not recognized by the antibodies, new exogenous
proteases that can cleave immunoglobulins, or a number of other
possiblefactorsthatwouldenhancetheestablishmentandcontin-
uation of an infection. There may be an advantage to S. pneu-
moniae to respond to the stress and danger of speciﬁc antibodies
with the ability to acquire new DNA. This is a prime area for
expansionforthePirofskilaboratoryfollowingtheirobservations
published in mBio (7).
The fact that an antibody can induce fratricide begs the ques-
tion of who enjoys the advantages of this interaction, the host or
the pathogen? Can S. pneumoniae beneﬁt from eliminating non-
competent cells in the hope that the surviving competent organ-
isms can have a chance to acquire a factor that would make them
resistant to the antibodies? This is another question to be an-
sweredasafollow-uptotheseintriguingobservations.Moreover,
what does this mean for pneumococcus? Is this bacterium helped
or harmed by the action of these antibodies? It would appear that
the altered gene expression consistent with fratricide could result
in fewer organisms, which in turn could act synergistically in the
clearingcapacityoftheopsonizingantibodies,beneﬁtingthehost.
On the other hand, an antibody effect that bestows increased ﬁt-
ness on the capacity for genetic exchange could result in acquired
resistance in much the same manner as it occurs with antibiotics,
beneﬁting the pathogen.
Indeed, the comparison with antibiotics in this antibody
mechanism is unavoidable. The data presented by Yano and co-
workersonthemechanismofactionofthenonopsonicantibodies
is reminiscent in general scope to the mechanism of action of
bacteriostatic antibiotics (7). Bacteriostatic antibiotics work indi-
rectly by weakening the bacteria so that the host response is more
effective.Infact,thefunctionalsimilaritybetweencertaintypesof
antibodies and antibiotics is already more than theory. The term
“antibiobodies” has been used to characterize anti-idiotypic re-
combinant antibodies that have toxin-like activity against fungal
pathogens (11–13).
Nonopsonic antibodies to S. pneumoniae also work indirectly
totriggerfratricideofatleastpartofthepopulationandthusallow
the host to clear the infection faster. Further studies of these new
andrevealingantibodyfunctionswilllikelyaddanotherchapterto
theburgeoningstoryofthediversityandversatilityoftheimmune
response to bacteria.
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